VDX-10 is patent-pending (Provisional App. No. 64/082,295). LyticGen Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. VDX-10 has not received FDA approval and is not available for commercial sale. Performance data reflects estimated properties based on analysis of peer-reviewed scientific literature on comparable CRISPR-enhanced bacteriophage systems; independent laboratory testing of VDX-10 has not been completed. Results may vary.  Disclaimer